WO2000077245A1 - Cell-based assay for screening cox-2 inhibitors - Google Patents

Cell-based assay for screening cox-2 inhibitors Download PDF

Info

Publication number
WO2000077245A1
WO2000077245A1 PCT/US2000/016486 US0016486W WO0077245A1 WO 2000077245 A1 WO2000077245 A1 WO 2000077245A1 US 0016486 W US0016486 W US 0016486W WO 0077245 A1 WO0077245 A1 WO 0077245A1
Authority
WO
WIPO (PCT)
Prior art keywords
cox
test substance
indicator cells
cells
arachidonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/016486
Other languages
French (fr)
Other versions
WO2000077245A9 (en
Inventor
E. Premkumar Reddy
M.V. Ramana Reddy
N. Dhanasekaran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Priority to US10/018,581 priority Critical patent/US6933128B1/en
Priority to EP00941446A priority patent/EP1187934A4/en
Priority to CA002374676A priority patent/CA2374676A1/en
Priority to AU56152/00A priority patent/AU5615200A/en
Publication of WO2000077245A1 publication Critical patent/WO2000077245A1/en
Anticipated expiration legal-status Critical
Publication of WO2000077245A9 publication Critical patent/WO2000077245A9/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • the invention relates to a method forthe identification of compounds having biological activity.
  • the invention relates to the identification of compounds which inhibit the activity of cycloxygenase-2.
  • heterotrimeric G proteins that transduce signals from cell surface receptors to intracellular effectors are composed of , ⁇ and ⁇ subunits.
  • G ⁇ subunits are grouped based on amino acid homology into four subfamilies: G s , G submit G q and G 12 (Strathman and Simon, Proc. Natl. Acad. Sci. (USA) 1991 ; 88:5582-5582).
  • the ⁇ subunits possess intrinsic GTPase activity and belong to a much larger group of GTPases which share structural elements.
  • a cycle of guanine nucleotide exchange and hydrolysis enables the protein to exist in two distinct states. The cycle allows G proteins to transiently relay signals from cell-surface receptors to intracellular effectors. Upon interaction with the appropriate agonist, the receptor serves to accelerate the exchange of GDP for GTP on the G protein ⁇ subunit.
  • the exchange is believed to be accompanied by dissociation of the ⁇ and ⁇ - ⁇ subunits, allowing ⁇ (and in some cases ⁇ - ⁇ ) to interact with effectors.
  • the intrinsic GTPase activity terminates the signal, returning the ⁇ subunit to its basal GDP-bound state.
  • Studies have suggested that the G 12 members ⁇ 12 and ⁇ 13 regulate signaling pathways involved in controlling cell growth and differentiation. See Vara Prasad et al., J. Biol. Chem. 1995, 270:18655-18659.
  • the full-length cDNAs encoding mouse G ⁇ 12 and G ⁇ 13, and the encoded translation products, are disclosed in Strathman and Simon, supra, the entire disclosure of which is incorporated herein by reference.
  • GTP-binding proteins When constitutively activated, GTP-binding proteins can induce neoplastic transformation. See Xu et al., Proc. Natl. Acad. Sci. (USA) 1993: 90:6741-6745, the entire disclosure of which is incorporated herein by reference.
  • Overexpression of wild-type G ⁇ 12 in NIH 3T3 cells is weakly transforming; a GTPase-deficient mutant of G ⁇ 12 (G ⁇ 12 Q229L) behaves as a potent oncogene and is highly transforming in NIH 3T3 cells (Xu et al., supra).
  • G ⁇ 12 -transfected cells exhibit a remarkably increased level of arachidonic acid in response to serum, and this effect is observed in cells transfected with either wild-type or activated mutant G ⁇ 12 (Xu et al. , supra).
  • the G ⁇ 12 Q229L mutant results from insertion of a leucine residue at position 229 in lieu of glutamine in the wild-type G ⁇ 12 protein.
  • the mutation occurs in a highly conserved region in G proteins which is involved in binding and GTPase activity.
  • the Q229L mutation results in a GTPase- deficient form of G ⁇ 12 .
  • the mutation blocks GTPase activity so that the ⁇ subunit binds GTP and is constitutively active (Xu et al., supra; Dhanasekaran et ai, J. Biol. Chem. 1993, 269:11802-11806; Jian et al., FEBS Lett.
  • Cyclooxygenase-1 (COX-1 ) and cyclooxygenase-2 (COX-2) are the enzymes which convert arachidonic acid into prostaglandins.
  • COX-1 is ubiquitously expressed and involved in cellular "housekeeping" functions of various tissues and organs.
  • COX-2 expression is rapidly induced in diverse cell types by different growth factors, mitogens, tumor promoters, and physiological stress stimuli. Transcriptional induction of COX-2 has been shown to be involved in different pathological conditions such as inflammation, pain, and fever. It has also been shown that the anti-inflammatory effects of aspirin and ibuprofen is through their inhibitory effect, albeit non-specific inhibitory effect, on COX-2. Furthermore, persistent activation of COX-2 has been shown to be associated with oncogenesis as well as the invasive potential of tumor cells.
  • Inhibitors of COX-2 are useful as therapeutics. See, for example, the discussion of the advantages of selective COX-2 inhibition set forth in U.S. Pat. 5,604,253.
  • COX-2 inhibition which relies on cells which respond to the presence of COX-2 inhibitor by increasing production of one or more prostaglandins in comparison to cells of the same type which are not contacted with COX-2 inhibitor.
  • a method for screening a test substance for COX-2 inhibitory activity is provided.
  • the test substance is contacted with indicator cells which constitutively or inducibly express endogenous COX-2.
  • the level of proliferation of the indicator cells is determined in the presence and absence of the test substance.
  • a decreased level of proliferation of the indicator cells in the presence of the test substance indicates that the test substance has COX-2 inhibitory activity.
  • the test substance is contacted with indicator cells which constitutively or inducibly express COX-2, and the level of one or more prostaglandins produced by the indicator cells is determined in the presence or absence of the test substance.
  • a decreased level of one or more prostaglandins produced by the indicator cells in the presence of a test substance indicates that the test substance has COX-2 inhibitory activity.
  • the test substance is contacted with indicator cells which constitutively or inducibly express COX-2, and the level of arachidonic acid provided by the indicator cells is determined in the presence or absence of the test substance.
  • An increased level of arachidonic acid provided by the indicator cells in the presence of a test substance indicates that the test substance has COX-2 inhibitory activity.
  • indicator cells constitutively or inducibly express endogenous COX-2.
  • the indicator cells express a GTPase-deficient mutant form of the ⁇ -subunit of protein G12.
  • the mutant ⁇ -subunit has the capacity to induce the production of arachidonic acid and COX-2 in the indicator cells.
  • the G12 protein c - subunit mutant comprises the Q229L mutation.
  • the level of indicator cell proliferation is conveniently determined by an assay for DNA synthesis by the indicator cells.
  • the DNA synthesis assay comprises assaying tritium-labeled thymidine uptake by the indicator cells.
  • the level of indicator cell production of one or more prostaglandins is conveniently determined with resort to any assay which is capable of quantifying, at least in relative terms as compared to control cells, the level of production of such prostaglandins.
  • the prostaglandin assay method comprises an immunoassay.
  • the immunoassay comprises a competitive immunoassay for a prostaglandin.
  • the level of arachidonic acid in the indicator cells, the components thereof, or released into the medium surrounding the cells, is conveniently determined with resort to any assay which is capable of quantifying, at least in relative terms as compared to control cells, the level of arachidonic acid.
  • One such method is a radiolabeling assay.
  • the assay comprises assaying release of tritiated arachidonic acid by the indicator cells.
  • Fig. 1 is a schematic representation of the mechanism by which
  • COX-2 plays a role in proliferation of cells expressing the GTPase-deficient G ⁇ 12 QL mutant.
  • Fig. 2A is a Northern blot of analysis of RNA from IPTG-inducible
  • G ⁇ 12 QL-NIH3T3 cells stimulated with 1 mM IPTG for 0, 0.5, 1 , 3 and 6 hours. Cells were probed with DNA encoding G ⁇ 12 QL, COX-2 or GAPDH.
  • Fig. 2B is similar to Fig. 2A, except that the analysis was carried out on control cells.
  • the control cells were NIH3T3 cells transfected with vector lacking the G ⁇ 12 QL insert.
  • Fig. 3 is Western blot analysis of cell lysates probed for COX-2 expression.
  • the lysates were prepared from G ⁇ 12 QL-NIH3T3 cells (lanes 3 and 6), control NIH3T3 cells (lanes 1 and 4) and G ⁇ 12 WT-NIH3T3 cells expressing wild type G ⁇ 12 (lanes 2 and 5).
  • Fig. 4 is a graph of [ 3 H]-thymidine incorporation as an index of DNA synthesis in NIH3T3 cells transfected with G ⁇ 12 QL DNA (G ⁇ 12 QL-NIH3T3) versus control NIH3T3 cells transfected with vector alone (pcDNA3-
  • Fig. 5 is a graph of prostaglandin release from NIH3T3 cells as a function of stable transfection with G ⁇ 12 QL expression vectors and pcDNA3. Values represent the mean ⁇ S.E. from a triplicate determination.
  • Fig. 6A is a graph of [ 3 H]-arachidonic acid release from G ⁇ 12 QL expression vector or pcDNA3 transfected NIH3T3 cells. Quiescent, stably transfected cells were stimulated with serum and [ 3 H]-arachidonic acid release was followed as a function of time. Values represent the mean
  • Fig.6B is a graph of [ 3 H]-arachidonic acid release from pcDNA3, ras, G ⁇ 12 QL, and G ⁇ 13 QL expression vector stably transfected NIH3T3 cells. Quiescent, transfected cells were stimulated with serum and [ 3 H]- arachidonic acid release was measured after 10 minutes. Values represent the mean ⁇ S.E. from a quadruplicate determination.
  • a cell based bioassay system for screening compounds for COX-2 inhibitory activity by assaying the growth-inhibitory property of the compounds when exposed to COX-2 growth-driven target cells.
  • the target cells are cells which are capable of growing in culture but which have been engineered to constitutively or inducibly express COX-2, preferably endogenous COX-2.
  • COX-2 expression with respect to COX-2 is meant the production of active COX-2 enzyme by the cell.
  • endogenous with respect to COX-2 is meant DNA sequences corresponding to the native, COX-2 gene locus, its variants, or derivatives present in the cells of the organism from which a given indicator cell line was derived.
  • COX-2 constitutive express
  • inducibly express with respect to COX-2 is meant that the COX- 2 gene is activated in response to a specific stimulus, such as the presence of a specific small molecule inducer, to produce biologically active COX-2 protein.
  • the gene is not activated, or activated only at a much lower level, in the absence of the specific stimulus.
  • Inducible expression of the COX-2 gene may be controlled directly to achieve inducible expression, such as by an inducible promoter operably linked to a COX-2 gene in an expression construct.
  • inducible expression of the COX-2 gene may be controlled indirectly, such as by an inducible promoter operably linked to a second gene other than the COX-2 gene. The inducible expression of the second gene in turn governs the expression of COX-2.
  • COX-2 is activated by several different pathways in the cell (Vane et al., Annu. Rev. Pharmacol. Toxicol. 1998; 38:97-120, incorporated herein by reference). Each pathway is a target for manipulation of COX-2 gene expression to achieve either constitutive or inducible expression of that gene.
  • Cell lines which express endogenous COX-2 and produce prostaglandins may be appropriate indicator cells for screening for COX-2 inhibitors.
  • An example of such a cell line is the MDA-MB-231 human breast cancer cell line (ATCC number HTB-26; Liu and Rose, Cancer Res. 1996; 56:5125-5127, incorporated herein by reference).
  • the indicator cells express a GTPase- deficient, constitutively-activated mutant form of the ⁇ -subunit of the heterotrimeric protein G12 ("G ⁇ 12 mutant").
  • GTPase-deficient is meant that the molecule lacks intrinsic GTPase activity.
  • the G ⁇ 12 mutant is constitutively active.
  • constitutively activate is meant that the activity of the protein is present essentially continually in the cell and is not subject to quantitative regulation.
  • the G ⁇ 12 mutant has the property of inducing the production of arachidonic acid.
  • Arachidonic acid is a substrate of COX-2.
  • COX-2 converts arachidonic acid into prostaglandins. The latter stimulate cell proliferation.
  • the G ⁇ 12 mutant also has the property of inducing the transcription of COX-2, which leads to the constitutive expression of COX-2 in cells engineered to express the mutant.
  • G ⁇ 12 QL protein G ⁇ 12 Q229L
  • the starting material for the G ⁇ 12 QL (also referred to herein as "Q229L") mutant is the full-length murine wild-type G ⁇ 12 cDNA disclosed by Strathman and Simon, Proc. Natl. Acad. Sci. (USA) 1991 ; 88:5582-5582 or GenBank accession record M63659.
  • the mutant is generated by the method described by Xu et al., supra, utilizing site-directed mutagenesis of double-stranded DNA by overlap extension using PCR methodology.
  • the mutagenic oligonucleotides have the following sequences, wherein the modified nucleotides are underlined: 5'-
  • Cells engineered to express G ⁇ 12 QL are driven to proliferation through an autocrine loop shown in Fig. 1.
  • COX-2 inhibitors can arrest cell proliferation by disrupting this autocrine loop. Such an inhibitory effect can be easily quantified by monitoring the G ⁇ 12 QL-stimulated synthesis of DNA.
  • a putative COX-2 inhibitor can thus be easily and rapidly screened for
  • a host cell line capable of growth in culture preferably a fibroblast line (e.g. NIH 3T3), is transfected with a construct which will drive G ⁇ 12 QL DNA expression in the host cell line.
  • the construct contains G ⁇ 12 QL DNA and appropriate control elements.
  • the construct may contain a non-inducible promoter, or an inducible promoter, e.g., an isopropyl- ⁇ -D-1-thiogalactopyranoside (IPTG)-inducible promoter.
  • COX-2 are then used as indicator cells for testing the COX-2 inhibitory activity of test substances.
  • the test substance may comprise a pure chemical compound or mixture of chemical compounds. Typically, the test substance will be an essentially pure chemical compound which may be contained in a suitable carrier for administration to the indicator cell culture. An appropriate concentration of test substance is introduced into the cell culture. An appropriate concentration can be determined by trial and error, without undue experimentation.
  • the concentration of test substance may range, for example, from about 0.1 to about 100 ⁇ M, more typically from about 1 to about 20 ⁇ M, most typically from about 1 to about 10 ⁇ M.
  • the level of proliferation of the indicator cells with and without the test substance present in the cell culture is then determined.
  • the test substance is contacted with the indicator cells under conditions which favor the proliferation of those cells.
  • Methods for culturing cells under conditions of proliferation are well-known to those skilled in the art.
  • conditions favoring cell proliferation in culture comprise culturing the cells in the presence of a growth medium, e.g., a growth medium comprising a serum such as fetal bovine serum (FBS).
  • Assays for determining the level of proliferation of cells in culture are well-known to those skilled in the art.
  • several indirect methods for assessing cell proliferation are known to those skilled in the art.
  • proliferation is assessed by monitoring DNA synthesis.
  • DNA synthesis may be conveniently monitored through the cell's uptake of detectably labeled DNA precursors.
  • labeled precursors include, for example, chemically- labeled and radiolabeled precursors.
  • One chemically labeled precursor is bromodeoxyuridine. Bromodeoxyuridine incorporation can be detected by bromodeoxyuridine-antibodies in an enzyme-linked immunosorbent assay using fixed microcultures (Muir et al., Analytical Biochemistry 1990; 185:377-382).
  • the preferred radiolabeled precursor is tritium-labeled thymidine ( 3 H-thymidine).
  • Other chemically labeled and radiolabeled DNA precursors suitable for use in cell proliferation assays are known to those skilled in the art.
  • the capacity of the test substance to inhibit cell proliferation is a measure of the potency of the substance as an inhibitor of COX-2 activity.
  • the level of one or more prostaglandins produced by the indicator cells, with and without the test substance present in the cell culture be can determined.
  • Such prostaglandins may include for example PGE 2 , PGF 2 ⁇ , PGD 2 , their stabilized chemical derivatives and the like. In samples were the chemical environment promotes the rapid turnover of prostaglandins such prostaglandins may be converted to stable derivatives prior to detection.
  • Such stabilized derivatives include for example bicyclo prostaglandin E2, 8-isoprostane, and prostaglandin D2 methoxime which correspond to PGE 2 , PGF 2 ⁇ ! and PGD 2 .
  • a decrease in production of prostaglandins by the indicator cells in the presence of the test substances indicates that the test substance has COX-2 inhibitory activity.
  • Assays for determining the level of prostaglandins produced by cells in culture are well-known to those skilled in the art. Such methods include, for example, chromatography- based techniques, receptor based assays or immunoassays for the prostaglandin(s) of interest. Receptor based prostaglandins assays may be based on the methods of Hanasaki et al. or Balapure et al. for example.
  • Prostaglandin production may be measured by the various methods in the media surrounding cells, in the cells themselves, or in a component of the cells.
  • Components of the cells include for example organelles, membranes, proteins, cell lysates, cell pellets, cell supematants and the like.
  • prostaglandin production in radiolabeled cells may be assayed by a thin layer chromatography (TLC) as follows. Radiolabeled prostaglandins are extracted from cells, their components, or the surrounding media with an appropriate solvent such as ethyl acetate. The solvent-extracted radiolabeled prostaglandins are then spotted on a TLC plate and developed under suitable conditions in an appropriate mobile phase. Radiolabeled prostaglandins may be detected by any suitable means such as phosporimaging, fluorography, scintillation counting, auto radiography and the like. Alternatives to TLC chromatography include any chromatography technique capable of discerning the relative amounts of prostaglandins produced by unlabeled or radiolabeled cells.
  • TLC thin layer chromatography
  • prostaglandin production by the indicator cells is measured by a competitive immunoassay.
  • a primary antibody specific to one or more prostaglandins is incubated with a sample to be analyzed followed by incubation of the sample with an immobilized secondary antibody specific to the primary antibody.
  • a labeled prostaglandin is then incubated with the sample, and the labeled prostaglandin is allowed to compete with non-conjugated prostaglandins in the sample for prostaglandin binding sites on the primary antibody.
  • the competing labeled prostaglandin may be labeled by any suitable means including radiolabeling, conjugation with a peroxidase or other easily detected polypeptide, chromophore labeling, orfluorophore labeling. Techniques for labeling prostaglandins are well known to those skilled in the art.
  • the level of competing, labeled prostaglandin bound after washing is inversely related to the amount of prostaglandin present in the sample analyzed. (Shaw and Ramwell, Methods of Biochem. Analysis 1969; 17:325-371 Green et al., Advances in Prostaglandin and Thromboxane Res. 1978 5:15-38; Powell, Prostaglandins 1980; 20:947-957; Kelly et al.
  • a competitive prostaglandin assay permits rapid, high throughput screening for COX-2 inhibitors using the indicator cells of the invention.
  • the level of arachidonic acid provided by the indicator cells is determined, with and without the test substance present in the cell culture.
  • a “level” of arachidonic acid which is "provided” by the indicator cells, is meant the relative amount or concentration of arachidonic acid in the cells or component thereof, or in the culture medium.
  • Arachidonic acid is readily converted to prostaglandins in the presence of functional COX-2.
  • An increase in the level of arachidonic acid by the indicator cells in the presence of the test substance indicates that the test substance has COX- 2 inhibitory activity.
  • Assays for determining the level of arachidonic acid produced by cells in culture are well-known to those skilled in the art. Arachidonic acid production may be measured in the media surrounding cells, in the cells themselves or in components of the cells.
  • arachidonic acid release is measured by labeling indicator cells with tritiated arachidonic acid ([ 3 H]- arachidonic acid), washing cells to remove free radiolabeled arachidonic acid, treating the cells with the test substances and after a time measuring by scintillation counting the radiolabeled arachidonic acid present in the media surrounding the cells.
  • tritiated arachidonic acid [ 3 H]- arachidonic acid
  • the radiolabelled arachadonic acid taken up by the cells is not converted to prostaglandin, but rather is released to the surrounding media.
  • the inhibitory compounds identified using the invention may be administered to individuals (animals, most particularly mammals including humans) afflicted with any disorder characterized by undesirable prostaglandin production resulting from cyclooxygenase activity, particularly COX-2 activity ("cyclooxygenase-mediated disorder").
  • COX-2 inhibitory compounds of the type identified using the invention are believed useful in treating infiamation and inflamation-related disorders, by administering to a subject having or susceptible to such infiamation or inflamation-related disorder and effective amount of an inhibitory compound.
  • Infiamation is associated with a variety of disease conditions. For a list of such disease conditions treatable by cyclooxygenase inhibitors, and COX-2 inhibitors in particular, see U.S.
  • Patents 5,604,253 and 5,908,852 the entire disclosures of which are incorporated herein by reference.
  • Such conditions include, for example, arthritis, including but not limited to rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis.
  • Such conditions further include rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, gout and ankylosing spondylitis, bursitis, and following surgical and dental procedures.
  • COX-2 inhibitory compounds are also believed useful as analgesics for treating or alleviating all forms of pain.
  • the compounds are believed useful in the treatment of other disorders including asthma, bronchitis, tendinitis, bursitis; skin related conditions such as psoriasis, eczema, burns and dermatitis; gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis and for the prevention of colorectal cancer; the treatment of infiamation in such diseases as vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, type I diabetes, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis, swelling occurring after injury, myocardial isch
  • COX-2 inhibitors of the type identified using the invention may inhibit cellular neoplastic transformations and metastatic tumor growth and hence can be used in the treatment of cancer.
  • neoplasia includes neoplasias that produce prostaglandins or express a cyclooxygenase, including both benign and cancerous tumors, growths and polyps. Neoplasias believed treatable with cyclooxygenase inhibitors are discussed in U. S. Pat. 5,972,986, the entire disclosure of which is incorporated herein by reference.
  • the COX-2 inhibitors identified using the invention may be used to inhibit the growth of an established neoplasm, i.e., to induce regression, or to prevent or delay the onset of the neoplasm.
  • neoplasias that produce prostaglandins include brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophageal cancer, small bowel cancer and stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamous cell and basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that effect epithelial cells throughout the body.
  • COX-2 inhibitory compounds identified by using the invention may also be useful in the treatment of angiogenesis-mediated disorders.
  • Angiogenesis-mediated disorders which may be treatable with cyclooxygenase inhibitors are discussed in U. S. Pat. 6,025,353, the entire disclosure of which is incorporated herein by reference. According to U. S. Pat.
  • such disorders include, for example, metastasis, corneal graft rejection, ocular neovascularization, retinal neovascularization, diabetic retinopathy, retrolental fibroplasia, neovascular glaucoma, gastric ulcer, infantile hemaginomas, angiofibroma of the nasopharynx, avascular necrosis of bone, and endometriosis.
  • Xbal (1.8 kb) fragment from pcDNA1- ⁇ 12 Q229L into the EcoRI-Xbal site of the pcDNA3 vector (Invitrogen, Carlsbad, CA).
  • Actively proliferating NIH 3T3 cells (1.5 x 10 6 cells/ 100 mm dish) grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS were transfected with 100 ng of the vector by the calcium precipitation method.
  • DMEM Dulbecco's modified Eagle's medium
  • NIH3T3 cell lines expressing inducible ⁇ 12 Q229L were established using the LacSwitch expression vectors (Stratagene). Briefly, NIH3T3 cell were cotransfected with p3'SS plasmid vector expressing the Lac repressor and pOPRSVI- ⁇ 12 Q229L vector by electroporation, as described by Vera Prasad et al., 1995. B. Preparation of COX-2 DNA
  • Murine COX-2 DNA was cloned using RT-PCR methods from the RNA prepared from NIH 3T3 cells pretreated (6 hrs) with 100 nM PMA using the following primers: 5'CTCTGCGATGCTCTTCCGAG-3' (SEQ ID NO:3) and 5'-GACTTTTACAGCTCAGTTGAACG-3' (SEQ ID NO:4).
  • the amplified 1827 bp PCR-product was sequenced and the comparison with the published sequences (Kujubu etal., J. Biol. Chem. 1991 , 266, 12866- 12872) confirmed the identity of COX-2 cDNA.
  • the COX-2 PCR-product was purified and cloned into pT7Blue TA vector (Novagen, Madison, WI). The clone was used as a source of probes for Northern blot analysis.
  • RNA was prepared from the cells following the published procedures of Dhanasekaran et al., J. Biol. Chem. 1993, 269:11802-11806, the entire disclosure of which is incorporated herein by reference. Twenty ⁇ g of the RNA (for each time point) was resolved in a denaturing 1 % agarose and 2.2 M formaldehyde gel.
  • RNA was blotted onto a zeta probe-GT membrane (Bio-Rad, CA) and cross-linked to the membrane by UV light.
  • the Hind lll-Xba I fragment (1.2 kbp) of G ⁇ 12 QL DNA excised from G ⁇ 12 QL and the Xba l-Bam HI fragment (1.8 kbp) of COX-2 from the COX-2pT7Blue vector were used as probes in Northern blot analyses.
  • the RNA was also probed for GAPDH expression.
  • Figs. 2A G ⁇ 12 QL-3NIH3T3
  • 2B control cells
  • the control cells were NIH3T3 cells transfected with "empty" pOPRSVI vector lacking the G ⁇ 12 QL insert. COX-2 transcription was induced only in G ⁇ 12 QL-NIH3T3 cells.
  • COX-2 protein The constitutive expression of COX-2 protein was demonstrated by Western blot analysis.
  • Cell lysates for Western blot analysis were prepared from control NIH3T3, NIH3T3 expressing wild type G ⁇ 12 (G ⁇ 12 WT-NIH3T3) and G ⁇ 12 QL-NIH3T3 cells.
  • PBS phosphate-buffered saline
  • the soluble proteins were cleared by centrifugation at 15, 000 g for 10 minutes at 4°C.
  • the lysate (50 ⁇ g) was resolved by SDS-PAGE and electroblotted onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA) in 10 mM 3-cyclohexylamino-1 -propane sulfonic acid (CAPS) buffer containing 10% methanol using a Mini-Protean apparatus (Bio-Rad, CA).
  • PVDF polyvinylidene fluoride
  • CAPS 3-cyclohexylamino-1 -propane sulfonic acid
  • the resolved lysates were probed with specific antibodies raised against the C- terminus of COX-2 (Oxford Biomedical Research, Ml).
  • COX-2 is constitutively expressed in G ⁇ 12 QL-NIH3T3 cells (lanes 3 and 6) but not in control NIH3T3 cells (lanes 1 and 4) or G ⁇ 12 WT-NIH3T3 cells (lanes 2 and 5).
  • Activation of prostaglandin release by NIH3T3 cells in response to G ⁇ 12 QL expression was determined by monitoring prostaglandin production.
  • Prostaglandin PGE 2 was used as an index of COX-2 mediated prostaglandin production.
  • Control NIH3T3 cells stably transfected with pcDNA3 vector and G ⁇ 12 QL-transformed NIH3T3 cells were plated at 3 x 10 6 cells per 100 mm dish and grown overnight at 37°C in DMEM containing 5 % FBS. The cells were washed and made quiescent by placing them in DMEM (+0.2 % BSA) without serum for an additional 24 hours. Cell growth was reinitiated by the addition of 10% FBS.
  • G ⁇ 12 QL dramatically activated prostaglandin PGE 2 production in the indicator cells in contrast to control NIH3T3 cells stably transfected with pcDNA3 as shown in Fig. 5.
  • Activation or inhibition of COX-2 activity in G ⁇ 12 QL transfected indicator cells can be assessed by determining the levels of prostaglandins produced by such indicator cells.
  • the assay may be used to screen candidate compounds for inhibition of COX-2 activity.
  • Arachidonic acid release levels can be used as an index of COX-2 activity.
  • Control NIH3T3 cells stably transfected with pcDNA3 vector and G ⁇ 12 QL-transformed NIH3T3 cells were plated at 2 x 10 4 cells per well in a 24-well plate and grown for 24 hours at 37 °C in DMEM containing 5 % FBS. Cells were labeled and made quiescent by incubation for 24 hrs with 0.5 ml serum free DMEM containing 10 mM HEPES (ph 7.4), 0.2 % BSA and 0.5 ⁇ C ⁇ [ 3 H]-arachidonic acid per well. Cells were then washed three times with PBS to remove free [ 3 H]-arachidonic acid.
  • Serum stimulation of G ⁇ 12 QL transfected cells dramatically increased arachidonic acid release in contrast to non-serum stimulated indicator cells as shown in Fig. 6A.
  • Arachidonic acid release by control NIH3T3 cells stably transfected with pcDNA3 was unaffected by serum stimulation as shown in Fig. 6A.
  • Activation or inhibition of COX-2 activity in G ⁇ 12 QL transfected indicator cells can be assessed by determining the levels of arachidonic acid produced by such indicator cells. Inhibition of
  • COX-2 will presumably increase arachidonic acid levels as such inhibition will prevent conversion of arachidonic acid into the various prostaglandins.
  • Arachidonic acid release levels were also used as an index of COX- 2 activity in NIH3T3 cells stably transfected with pcDNA3, ras, G ⁇ 12 QL, and G ⁇ 13 QL expression vectors as shown in Fig. 6B.
  • Cells were plated, labeled with [ 3 H]-arachidonic acid, and [ 3 H]-arachidonic acid release was measured using the methodologies described above.
  • [ 3 H]-arachidonic acid release was measured by scintillation counting 10 min after reinitiation of cell growth by addition of 5% FBS. The results are shown in Fig. 6B. The values represent the mean + the standard error for quadruplicate determinations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A cell-based assay is provided for screening substances for the capacity to inhibit COX-2 activity. The assay utilizes as a screening reagent a cell line which has been engineered to achieve constitutive or inducible expression of COX-2. In one embodiment, the cells express a GTPase-deficient, constitutively-activated mutant form of the α-subunit of protein G12 which induces the production of arachidonic acid and COX-2. Decreased cell proliferation in the presence of test substance indicates that the substance has COX-2 inhibitory activity.

Description

CELL-BASED ASSAY FOR SCREENING COX-2 INHIBITORS
Cross-Reference to Related Application
The benefit of the filing date of U.S. provisional patent application Ser. No. 60/139,569 filed June 16, 1999 is hereby claimed pursuant to 35 U.S.C. 119(e). The entire disclosure of the aforesaid provisional application is incorporated herein by reference.
Reference to Government Grant
The invention described herein was supported in part by National Institutes of Health grant GM49897. The U.S. government has certain rights in the invention.
Field of the Invention
The invention relates to a method forthe identification of compounds having biological activity. In particular, the invention relates to the identification of compounds which inhibit the activity of cycloxygenase-2.
Background of the Invention
Heterotrimeric G Protein
Heterotrimeric guanine nucleotide-binding regulatory proteins
("heterotrimeric G proteins") that transduce signals from cell surface receptors to intracellular effectors are composed of , β and γ subunits.
Gα subunits are grouped based on amino acid homology into four subfamilies: Gs, G„ Gq and G12 (Strathman and Simon, Proc. Natl. Acad. Sci. (USA) 1991 ; 88:5582-5582). The α subunits possess intrinsic GTPase activity and belong to a much larger group of GTPases which share structural elements. In all of these GTPases, a cycle of guanine nucleotide exchange and hydrolysis enables the protein to exist in two distinct states. The cycle allows G proteins to transiently relay signals from cell-surface receptors to intracellular effectors. Upon interaction with the appropriate agonist, the receptor serves to accelerate the exchange of GDP for GTP on the G protein α subunit. The exchange is believed to be accompanied by dissociation of the α and β-γ subunits, allowing α (and in some cases β- γ) to interact with effectors. The intrinsic GTPase activity terminates the signal, returning the α subunit to its basal GDP-bound state. Studies have suggested that the G12 members α12 and α13 regulate signaling pathways involved in controlling cell growth and differentiation. See Vara Prasad et al., J. Biol. Chem. 1995, 270:18655-18659. The full-length cDNAs encoding mouse Gα12 and Gα13, and the encoded translation products, are disclosed in Strathman and Simon, supra, the entire disclosure of which is incorporated herein by reference.
The sequences have been deposited in the GenBank data base by the authors, accession nos. M63659 (Gα12) and M63660 (Gα13). Those GenBank records are incorporated herein by reference. The human Gα12 cDNA has also been cloned (Chan etal., Mol. Cell. Biol. 1993; 13:762-768, incorporated herein by reference).
When constitutively activated, GTP-binding proteins can induce neoplastic transformation. See Xu et al., Proc. Natl. Acad. Sci. (USA) 1993: 90:6741-6745, the entire disclosure of which is incorporated herein by reference. Overexpression of wild-type Gα12 in NIH 3T3 cells is weakly transforming; a GTPase-deficient mutant of Gα12 (Gα12Q229L) behaves as a potent oncogene and is highly transforming in NIH 3T3 cells (Xu et al., supra). It has been found that Gα12-transfected cells exhibit a remarkably increased level of arachidonic acid in response to serum, and this effect is observed in cells transfected with either wild-type or activated mutant Gα12 (Xu et al. , supra).
The Gα12Q229L mutant results from insertion of a leucine residue at position 229 in lieu of glutamine in the wild-type Gα12 protein. The mutation occurs in a highly conserved region in G proteins which is involved in binding and GTPase activity. The Q229L mutation results in a GTPase- deficient form of Gα12. The mutation blocks GTPase activity so that the α subunit binds GTP and is constitutively active (Xu et al., supra; Dhanasekaran et ai, J. Biol. Chem. 1993, 269:11802-11806; Jian et al., FEBS Lett. 1993; 330:319-322; Vara Prasad et al,, Oncogene 1994, 9:2425-2429; Voyno-Yasenetskaya et al., Oncogene 1994; 9:2559-2565).
COX-2
Cyclooxygenase-1 (COX-1 ) and cyclooxygenase-2 (COX-2) are the enzymes which convert arachidonic acid into prostaglandins. COX-1 is ubiquitously expressed and involved in cellular "housekeeping" functions of various tissues and organs. In contrast, COX-2 expression is rapidly induced in diverse cell types by different growth factors, mitogens, tumor promoters, and physiological stress stimuli. Transcriptional induction of COX-2 has been shown to be involved in different pathological conditions such as inflammation, pain, and fever. It has also been shown that the anti-inflammatory effects of aspirin and ibuprofen is through their inhibitory effect, albeit non-specific inhibitory effect, on COX-2. Furthermore, persistent activation of COX-2 has been shown to be associated with oncogenesis as well as the invasive potential of tumor cells.
Inhibitors of COX-2 are useful as therapeutics. See, for example, the discussion of the advantages of selective COX-2 inhibition set forth in U.S. Pat. 5,604,253.
What is needed is a simple, sensitive and rapid screening method for determining the COX-2 inhibitory activity of therapeutic candidates. Summary of the Invention
It is an object of the invention to provide a screening method to determine the COX-2 inhibitory activity of chemical compounds.
It is an object of the invention to provide a screening method for COX-2 inhibition which relies on cells which respond to the presence of COX-2 inhibitor by reducing proliferation in comparison to cells of the same type which are not contacted with COX-2 inhibitor.
It is an object of the invention to provide a screening method for
COX-2 inhibition which relies on cells which respond to the presence of COX-2 inhibitor by increasing production of one or more prostaglandins in comparison to cells of the same type which are not contacted with COX-2 inhibitor.
It is an object of the invention to provide a screening method for COX-2 inhibition which relies on cells which respond to the presence of COX-2 inhibitor by accumulating arachidonic acid in comparison to cells of the same type which are not contacted with COX-2 inhibitor.
A method for screening a test substance for COX-2 inhibitory activity is provided. The test substance is contacted with indicator cells which constitutively or inducibly express endogenous COX-2. The level of proliferation of the indicator cells is determined in the presence and absence of the test substance. A decreased level of proliferation of the indicator cells in the presence of the test substance indicates that the test substance has COX-2 inhibitory activity.
According to another method for screening a test substance for COX-2 inhibitory activity, the test substance is contacted with indicator cells which constitutively or inducibly express COX-2, and the level of one or more prostaglandins produced by the indicator cells is determined in the presence or absence of the test substance. A decreased level of one or more prostaglandins produced by the indicator cells in the presence of a test substance indicates that the test substance has COX-2 inhibitory activity.
According to another method for screening a test substance for COX-2 inhibitory activity, the test substance is contacted with indicator cells which constitutively or inducibly express COX-2, and the level of arachidonic acid provided by the indicator cells is determined in the presence or absence of the test substance. An increased level of arachidonic acid provided by the indicator cells in the presence of a test substance indicates that the test substance has COX-2 inhibitory activity. According to preferred embodiments of the invention, indicator cells constitutively or inducibly express endogenous COX-2. According to other preferred embodiments of the invention, the indicator cells express a GTPase-deficient mutant form of the α-subunit of protein G12. The mutant α-subunit has the capacity to induce the production of arachidonic acid and COX-2 in the indicator cells. According to one embodiment of the invention, the G12 protein c - subunit mutant comprises the Q229L mutation.
The level of indicator cell proliferation is conveniently determined by an assay for DNA synthesis by the indicator cells. According to one embodiment, the DNA synthesis assay comprises assaying tritium-labeled thymidine uptake by the indicator cells.
The level of indicator cell production of one or more prostaglandins is conveniently determined with resort to any assay which is capable of quantifying, at least in relative terms as compared to control cells, the level of production of such prostaglandins. According to a preferred embodiment, the prostaglandin assay method comprises an immunoassay. According to a more preferred embodiment, the immunoassay comprises a competitive immunoassay for a prostaglandin.
The level of arachidonic acid in the indicator cells, the components thereof, or released into the medium surrounding the cells, is conveniently determined with resort to any assay which is capable of quantifying, at least in relative terms as compared to control cells, the level of arachidonic acid. One such method is a radiolabeling assay. According to one embodiment, the assay comprises assaying release of tritiated arachidonic acid by the indicator cells.
Description of the Figures Fig. 1 is a schematic representation of the mechanism by which
COX-2 plays a role in proliferation of cells expressing the GTPase-deficient Gα12QL mutant.
Fig. 2A is a Northern blot of analysis of RNA from IPTG-inducible
Gα12QL-NIH3T3 cells stimulated with 1 mM IPTG for 0, 0.5, 1 , 3 and 6 hours. Cells were probed with DNA encoding Gα12QL, COX-2 or GAPDH.
Fig. 2B is similar to Fig. 2A, except that the analysis was carried out on control cells. The control cells were NIH3T3 cells transfected with vector lacking the Gα12QL insert.
Fig. 3 is Western blot analysis of cell lysates probed for COX-2 expression. The lysates were prepared from Gα12QL-NIH3T3 cells (lanes 3 and 6), control NIH3T3 cells (lanes 1 and 4) and Gα12WT-NIH3T3 cells expressing wild type Gα12 (lanes 2 and 5).
Fig. 4 is a graph of [3H]-thymidine incorporation as an index of DNA synthesis in NIH3T3 cells transfected with Gα12QL DNA (Gα12QL-NIH3T3) versus control NIH3T3 cells transfected with vector alone (pcDNA3-
NIH3T3). Values represent the mean ±S.E. from a triplicate determination.
Fig. 5 is a graph of prostaglandin release from NIH3T3 cells as a function of stable transfection with Gα12QL expression vectors and pcDNA3. Values represent the mean ±S.E. from a triplicate determination. Fig. 6A is a graph of [3H]-arachidonic acid release from Gα12QL expression vector or pcDNA3 transfected NIH3T3 cells. Quiescent, stably transfected cells were stimulated with serum and [3H]-arachidonic acid release was followed as a function of time. Values represent the mean
±S.E. from a triplicate determination. Fig.6B is a graph of [3H]-arachidonic acid release from pcDNA3, ras, Gα12QL, and Gα13QL expression vector stably transfected NIH3T3 cells. Quiescent, transfected cells were stimulated with serum and [3H]- arachidonic acid release was measured after 10 minutes. Values represent the mean ±S.E. from a quadruplicate determination.
Detailed Description of the Invention
A cell based bioassay system is provided for screening compounds for COX-2 inhibitory activity by assaying the growth-inhibitory property of the compounds when exposed to COX-2 growth-driven target cells. The target cells are cells which are capable of growing in culture but which have been engineered to constitutively or inducibly express COX-2, preferably endogenous COX-2.
By "expression" with respect to COX-2 is meant the production of active COX-2 enzyme by the cell.
By "endogenous" with respect to COX-2 is meant DNA sequences corresponding to the native, COX-2 gene locus, its variants, or derivatives present in the cells of the organism from which a given indicator cell line was derived.
By "constitutively express" with respect to COX-2 is meant that biologically active COX-2 protein is present continually in a cell and does not appear to be subject to quantitative regulation.
By "inducibly express" with respect to COX-2 is meant that the COX- 2 gene is activated in response to a specific stimulus, such as the presence of a specific small molecule inducer, to produce biologically active COX-2 protein. The gene is not activated, or activated only at a much lower level, in the absence of the specific stimulus. Inducible expression of the COX-2 gene may be controlled directly to achieve inducible expression, such as by an inducible promoter operably linked to a COX-2 gene in an expression construct. Alternatively, inducible expression of the COX-2 gene may be controlled indirectly, such as by an inducible promoter operably linked to a second gene other than the COX-2 gene. The inducible expression of the second gene in turn governs the expression of COX-2.
COX-2 is activated by several different pathways in the cell (Vane et al., Annu. Rev. Pharmacol. Toxicol. 1998; 38:97-120, incorporated herein by reference). Each pathway is a target for manipulation of COX-2 gene expression to achieve either constitutive or inducible expression of that gene. Cell lines which express endogenous COX-2 and produce prostaglandins may be appropriate indicator cells for screening for COX-2 inhibitors. An example of such a cell line is the MDA-MB-231 human breast cancer cell line (ATCC number HTB-26; Liu and Rose, Cancer Res. 1996; 56:5125-5127, incorporated herein by reference).
According to one embodiment, the indicator cells express a GTPase- deficient, constitutively-activated mutant form of the α-subunit of the heterotrimeric protein G12 ("Gα12 mutant"). By "GTPase-deficient" is meant that the molecule lacks intrinsic GTPase activity. Hence, the Gα12 mutant is constitutively active. By "constitutively activate" is meant that the activity of the protein is present essentially continually in the cell and is not subject to quantitative regulation. The Gα12 mutant has the property of inducing the production of arachidonic acid. Arachidonic acid is a substrate of COX-2. COX-2 converts arachidonic acid into prostaglandins. The latter stimulate cell proliferation. The Gα12 mutant also has the property of inducing the transcription of COX-2, which leads to the constitutive expression of COX-2 in cells engineered to express the mutant.
Contact of indicator cells with an inhibitor of COX-2 has the effect of inhibiting production of prostaglandins, and thus cell proliferation. At the same time, the prostaglandin precursor arachidonic acid will accumulate in the cell or culture medium due to the blockage of COX-2-mediated conversion of arachidonic acid to prostaglandin.
One such Gα12 mutant is the protein Gα12Q229L ("Gα12QL") described by Xu et al., supra. The starting material for the Gα12QL (also referred to herein as "Q229L") mutant is the full-length murine wild-type Gα12 cDNA disclosed by Strathman and Simon, Proc. Natl. Acad. Sci. (USA) 1991 ; 88:5582-5582 or GenBank accession record M63659. The mutant is generated by the method described by Xu et al., supra, utilizing site-directed mutagenesis of double-stranded DNA by overlap extension using PCR methodology. The mutagenic oligonucleotides have the following sequences, wherein the modified nucleotides are underlined: 5'-
TGGGCGGCCIGAGGTCAC-3 ' (SEQ I D NO: 1 ) and 5'-
GTGACCTCAGGCCGCCCA-3' (SEQ ID NO:2).
Cells engineered to express Gα12QL are driven to proliferation through an autocrine loop shown in Fig. 1. COX-2 inhibitors can arrest cell proliferation by disrupting this autocrine loop. Such an inhibitory effect can be easily quantified by monitoring the Gα12QL-stimulated synthesis of DNA.
A putative COX-2 inhibitor can thus be easily and rapidly screened for
COX-2 inhibitory activity.
Prior to the present invention, it was not known that the Q229L mutation induces COX-2 transcription in cells. It has been unexpectedly found that Gα12QL-transformed cells constitutively express COX-2, thereby permitting their use as reagents for screening putative COX-2 inhibitors. According to the invention, a host cell line capable of growth in culture, preferably a fibroblast line (e.g. NIH 3T3), is transfected with a construct which will drive Gα12QL DNA expression in the host cell line. The construct contains Gα12QL DNA and appropriate control elements. The construct may contain a non-inducible promoter, or an inducible promoter, e.g., an isopropyl-β-D-1-thiogalactopyranoside (IPTG)-inducible promoter.
Methods for establishing cell lines that expresses Gα12QL under control of an IPTG promoter are described by Vara Prasad et al., J. Biol. Chem.
1995, 270:18655-18659, the entire disclosure of which is incorporated herein by reference.
Cells of the transfected cell line which produce arachidonic acid and
COX-2 are then used as indicator cells for testing the COX-2 inhibitory activity of test substances. The test substance may comprise a pure chemical compound or mixture of chemical compounds. Typically, the test substance will be an essentially pure chemical compound which may be contained in a suitable carrier for administration to the indicator cell culture. An appropriate concentration of test substance is introduced into the cell culture. An appropriate concentration can be determined by trial and error, without undue experimentation. The concentration of test substance may range, for example, from about 0.1 to about 100 μM, more typically from about 1 to about 20 μM, most typically from about 1 to about 10 μM.
According to one embodiment of the invention, the level of proliferation of the indicator cells with and without the test substance present in the cell culture is then determined. The test substance is contacted with the indicator cells under conditions which favor the proliferation of those cells. Methods for culturing cells under conditions of proliferation are well-known to those skilled in the art. Typically, conditions favoring cell proliferation in culture comprise culturing the cells in the presence of a growth medium, e.g., a growth medium comprising a serum such as fetal bovine serum (FBS). Assays for determining the level of proliferation of cells in culture are well-known to those skilled in the art. In addition to determining actual cell number, several indirect methods for assessing cell proliferation are known to those skilled in the art. According to one preferred embodiment of a proliferation assay, proliferation is assessed by monitoring DNA synthesis. Proliferating cells actively synthesize DNA to support mitosis. DNA synthesis may be conveniently monitored through the cell's uptake of detectably labeled DNA precursors. Such labeled precursors include, for example, chemically- labeled and radiolabeled precursors. One chemically labeled precursor is bromodeoxyuridine. Bromodeoxyuridine incorporation can be detected by bromodeoxyuridine-antibodies in an enzyme-linked immunosorbent assay using fixed microcultures (Muir et al., Analytical Biochemistry 1990; 185:377-382). The preferred radiolabeled precursor is tritium-labeled thymidine (3H-thymidine). Other chemically labeled and radiolabeled DNA precursors suitable for use in cell proliferation assays are known to those skilled in the art. The capacity of the test substance to inhibit cell proliferation is a measure of the potency of the substance as an inhibitor of COX-2 activity.
According to another embodiment of the invention, the level of one or more prostaglandins produced by the indicator cells, with and without the test substance present in the cell culture, be can determined. Such prostaglandins may include for example PGE2, PGF2α, PGD2, their stabilized chemical derivatives and the like. In samples were the chemical environment promotes the rapid turnover of prostaglandins such prostaglandins may be converted to stable derivatives prior to detection. Such stabilized derivatives include for example bicyclo prostaglandin E2, 8-isoprostane, and prostaglandin D2 methoxime which correspond to PGE2, PGF2α! and PGD2. A decrease in production of prostaglandins by the indicator cells in the presence of the test substances indicates that the test substance has COX-2 inhibitory activity. Assays for determining the level of prostaglandins produced by cells in culture are well-known to those skilled in the art. Such methods include, for example, chromatography- based techniques, receptor based assays or immunoassays for the prostaglandin(s) of interest. Receptor based prostaglandins assays may be based on the methods of Hanasaki et al. or Balapure et al. for example.
Hanasaki et ai, J. Biol. Chem. 1990;265:4871-4875 and Balapure et al.,
Biochem. Pharmacol. 1989;38:2375-2381. Prostaglandin production may be measured by the various methods in the media surrounding cells, in the cells themselves, or in a component of the cells. Components of the cells include for example organelles, membranes, proteins, cell lysates, cell pellets, cell supematants and the like.
For example, prostaglandin production in radiolabeled cells may be assayed by a thin layer chromatography (TLC) as follows. Radiolabeled prostaglandins are extracted from cells, their components, or the surrounding media with an appropriate solvent such as ethyl acetate. The solvent-extracted radiolabeled prostaglandins are then spotted on a TLC plate and developed under suitable conditions in an appropriate mobile phase. Radiolabeled prostaglandins may be detected by any suitable means such as phosporimaging, fluorography, scintillation counting, auto radiography and the like. Alternatives to TLC chromatography include any chromatography technique capable of discerning the relative amounts of prostaglandins produced by unlabeled or radiolabeled cells.
According to one preferred embodiment of the invention, prostaglandin production by the indicator cells is measured by a competitive immunoassay. In such an assay, a primary antibody specific to one or more prostaglandins is incubated with a sample to be analyzed followed by incubation of the sample with an immobilized secondary antibody specific to the primary antibody. A labeled prostaglandin is then incubated with the sample, and the labeled prostaglandin is allowed to compete with non-conjugated prostaglandins in the sample for prostaglandin binding sites on the primary antibody. The competing labeled prostaglandin may be labeled by any suitable means including radiolabeling, conjugation with a peroxidase or other easily detected polypeptide, chromophore labeling, orfluorophore labeling. Techniques for labeling prostaglandins are well known to those skilled in the art. The level of competing, labeled prostaglandin bound after washing is inversely related to the amount of prostaglandin present in the sample analyzed. (Shaw and Ramwell, Methods of Biochem. Analysis 1969; 17:325-371 Green et al., Advances in Prostaglandin and Thromboxane Res. 1978 5:15-38; Powell, Prostaglandins 1980; 20:947-957; Kelly et al. Prostaglandins, Leukotrienes and Essential Fatty Acids 1989; 37:187-191 Granstrom and Kindhal, Advances in Prostaglandin and Thromboxane Res 1980; 5:119-210; Morris et al., Prostaglandins 1981 ; 21 :771-778 Granstrom and Samuelsson, Advances in Prostaglandin and Thromboxane Res. 1978; 5:1-13). A competitive prostaglandin assay permits rapid, high throughput screening for COX-2 inhibitors using the indicator cells of the invention. As an alternative to measuring prostaglandin production by the indicator cells, the level of arachidonic acid provided by the indicator cells is determined, with and without the test substance present in the cell culture. By a "level" of arachidonic acid which is "provided" by the indicator cells, is meant the relative amount or concentration of arachidonic acid in the cells or component thereof, or in the culture medium. Arachidonic acid is readily converted to prostaglandins in the presence of functional COX-2. An increase in the level of arachidonic acid by the indicator cells in the presence of the test substance indicates that the test substance has COX- 2 inhibitory activity. Assays for determining the level of arachidonic acid produced by cells in culture are well-known to those skilled in the art. Arachidonic acid production may be measured in the media surrounding cells, in the cells themselves or in components of the cells. According to one preferred embodiment of the invention, arachidonic acid release is measured by labeling indicator cells with tritiated arachidonic acid ([3H]- arachidonic acid), washing cells to remove free radiolabeled arachidonic acid, treating the cells with the test substances and after a time measuring by scintillation counting the radiolabeled arachidonic acid present in the media surrounding the cells. (Xu et al., supra). In the absence of functioning COX-2 the radiolabelled arachadonic acid taken up by the cells is not converted to prostaglandin, but rather is released to the surrounding media.
The inhibitory compounds identified using the invention may be administered to individuals (animals, most particularly mammals including humans) afflicted with any disorder characterized by undesirable prostaglandin production resulting from cyclooxygenase activity, particularly COX-2 activity ("cyclooxygenase-mediated disorder"). In particular, COX-2 inhibitory compounds of the type identified using the invention are believed useful in treating infiamation and inflamation-related disorders, by administering to a subject having or susceptible to such infiamation or inflamation-related disorder and effective amount of an inhibitory compound. Infiamation is associated with a variety of disease conditions. For a list of such disease conditions treatable by cyclooxygenase inhibitors, and COX-2 inhibitors in particular, see U.S. Patents 5,604,253 and 5,908,852, the entire disclosures of which are incorporated herein by reference. Such conditions include, for example, arthritis, including but not limited to rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis. Such conditions further include rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, gout and ankylosing spondylitis, bursitis, and following surgical and dental procedures. COX-2 inhibitory compounds are also believed useful as analgesics for treating or alleviating all forms of pain. The compounds are believed useful in the treatment of other disorders including asthma, bronchitis, tendinitis, bursitis; skin related conditions such as psoriasis, eczema, burns and dermatitis; gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis and for the prevention of colorectal cancer; the treatment of infiamation in such diseases as vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, type I diabetes, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis, swelling occurring after injury, myocardial ischemia, and the like. The COX-2 inhibitory compounds identified using the invention are also believed useful as antipyretics forthe treatment of fever.
In addition, COX-2 inhibitors of the type identified using the invention may inhibit cellular neoplastic transformations and metastatic tumor growth and hence can be used in the treatment of cancer. The term "neoplasia" includes neoplasias that produce prostaglandins or express a cyclooxygenase, including both benign and cancerous tumors, growths and polyps. Neoplasias believed treatable with cyclooxygenase inhibitors are discussed in U. S. Pat. 5,972,986, the entire disclosure of which is incorporated herein by reference. The COX-2 inhibitors identified using the invention may be used to inhibit the growth of an established neoplasm, i.e., to induce regression, or to prevent or delay the onset of the neoplasm. According to U.S. Pat. 5,972,986, neoplasias that produce prostaglandins, and which are therefore believed treatable with compounds of the type identified using the invention, include brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophageal cancer, small bowel cancer and stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamous cell and basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that effect epithelial cells throughout the body.
The COX-2 inhibitory compounds identified by using the invention may also be useful in the treatment of angiogenesis-mediated disorders. Angiogenesis-mediated disorders which may be treatable with cyclooxygenase inhibitors are discussed in U. S. Pat. 6,025,353, the entire disclosure of which is incorporated herein by reference. According to U. S. Pat. 6,025,353, such disorders include, for example, metastasis, corneal graft rejection, ocular neovascularization, retinal neovascularization, diabetic retinopathy, retrolental fibroplasia, neovascular glaucoma, gastric ulcer, infantile hemaginomas, angiofibroma of the nasopharynx, avascular necrosis of bone, and endometriosis.
The practice of the invention is illustrated by the following non- limiting examples. Example 1 Establishing Gα1?QL Cell Line
A. Transfection of NIH3T3 Cells with Gα^QL Vector (i) Preparation of Gα1?QL-NIH3T3 The vector Gα12QL-pcDNA3 was prepared by ligating the EcoRI-
Xbal (1.8 kb) fragment from pcDNA1-α12Q229L into the EcoRI-Xbal site of the pcDNA3 vector (Invitrogen, Carlsbad, CA). Actively proliferating NIH 3T3 cells (1.5 x 106 cells/ 100 mm dish) grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS were transfected with 100 ng of the vector by the calcium precipitation method. The procedures for transfection and transformation of NIH 3T3 cells have been previously described (Vara Prasad et ai, Oncogene 1994, 9:2425-2429, and Shore & Reddy, Oncogene 1989, 4:1411-1423, the entire disclosures of which are incorporated herein by reference.) Individual transformed foci were isolated and expanded for further analysis by Northern and Western analyses for Gα12QL expression as well as anchorage-independent growth in soft-agar according to previously published procedures (Vara Prasad et al., 1994, supra).
(ii) Preparation of IPTG-inducible Gα^QL-NIHSTS An NIH3T3 cell line that expresses Gα12QL under an IPTG-inducible promoter (Gα12QL-pOPRSVI-NIH3T3) was established as previously described (Vera Prasad et al., 1995, supra), as follows. Blunt-ended 1.8 kb Hindlll-Xbal fragment of α12Q229L excised from the Gα12QL-pcDNA3 vector was ligated into the blunted Notl site of the pOPRSVI plasmid following published procedures (Sambrook etal. (1989) Molecular Cloning: A Laboratory Manual 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). NIH3T3 cell lines expressing inducible α12Q229L were established using the LacSwitch expression vectors (Stratagene). Briefly, NIH3T3 cell were cotransfected with p3'SS plasmid vector expressing the Lac repressor and pOPRSVI-α12Q229L vector by electroporation, as described by Vera Prasad et al., 1995. B. Preparation of COX-2 DNA
Murine COX-2 DNA was cloned using RT-PCR methods from the RNA prepared from NIH 3T3 cells pretreated (6 hrs) with 100 nM PMA using the following primers: 5'CTCTGCGATGCTCTTCCGAG-3' (SEQ ID NO:3) and 5'-GACTTTTACAGCTCAGTTGAACG-3' (SEQ ID NO:4). The amplified 1827 bp PCR-product was sequenced and the comparison with the published sequences (Kujubu etal., J. Biol. Chem. 1991 , 266, 12866- 12872) confirmed the identity of COX-2 cDNA. The COX-2 PCR-product was purified and cloned into pT7Blue TA vector (Novagen, Madison, WI). The clone was used as a source of probes for Northern blot analysis.
C. Confirmation of COX-2 Expression in IPTG-inducible Gα12QL- NIH3T3 Cells
1. Northern Blotting
Expression of Gα12QL was induced in the IPTG-inducibleGα12-QL- NIH3T3 cells and control cells by the addition of 1 mM IPTG. At O, 0.5, 1 , 3, and 6 hours after the addition of IPTG, total RNA was prepared from the cells following the published procedures of Dhanasekaran et al., J. Biol. Chem. 1993, 269:11802-11806, the entire disclosure of which is incorporated herein by reference. Twenty μg of the RNA (for each time point) was resolved in a denaturing 1 % agarose and 2.2 M formaldehyde gel. The RNA was blotted onto a zeta probe-GT membrane (Bio-Rad, CA) and cross-linked to the membrane by UV light. The Hind lll-Xba I fragment (1.2 kbp) of Gα12QL DNA excised from Gα12QL and the Xba l-Bam HI fragment (1.8 kbp) of COX-2 from the COX-2pT7Blue vector were used as probes in Northern blot analyses. The RNA was also probed for GAPDH expression.
The results of the Northern blot analysis are shown in Figs. 2A (Gα12QL-3NIH3T3) and 2B (control cells). The control cells were NIH3T3 cells transfected with "empty" pOPRSVI vector lacking the Gα12QL insert. COX-2 transcription was induced only in Gα12QL-NIH3T3 cells.
2. Western Blotting
The constitutive expression of COX-2 protein was demonstrated by Western blot analysis. Cell lysates for Western blot analysis were prepared from control NIH3T3, NIH3T3 expressing wild type Gα12 (Gα12WT-NIH3T3) and Gα12QL-NIH3T3 cells. The cells grown in 100 mm dishes, washed twice in phosphate-buffered saline (PBS) and lysed with 0.5 ml of RIPA buffer (10 mM NaPO4 pH 7,0, 150 mM NaCl, 2 mM EDTA, 1% sodium deoxycholate, 1 % NP40, 0.1% SDS, 50 mM NaF, 200 mM Na3VO4, 0.1 % β-mercaptoethanol, 1 mM phenylmethanesulfonyl- fluoride (PMSF), 4 μg/ml aprotinin, and 2 μg/ml leupeptin). The soluble proteins were cleared by centrifugation at 15, 000 g for 10 minutes at 4°C. The lysate (50 μg) was resolved by SDS-PAGE and electroblotted onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA) in 10 mM 3-cyclohexylamino-1 -propane sulfonic acid (CAPS) buffer containing 10% methanol using a Mini-Protean apparatus (Bio-Rad, CA). The resolved lysates were probed with specific antibodies raised against the C- terminus of COX-2 (Oxford Biomedical Research, Ml).
The results are shown in Fig. 3. COX-2 is constitutively expressed in Gα12QL-NIH3T3 cells (lanes 3 and 6) but not in control NIH3T3 cells (lanes 1 and 4) or Gα12WT-NIH3T3 cells (lanes 2 and 5).
Example 2 Inhibition of Gα,,QL-NIH3T3 Cell Proliferation by COX-2 Inhibitor
Inhibition of Gα12QL-NIH3T3 cell proliferation by a COX-2 inhibitor was determined by monitoring DNA synthesis. [3H]-Thymidine incorporation was used as an index of DNA-synthesis. Control cells (expressing pcDNA3 vector) and Gα12QL-transformed NIH 3T3 cells were plated at 5 x 104 cells per well in a 24-well plate and grown for 24 hours at 37°C in DMEM containing 5 % FBS. The cells were washed and made quiescent by placing them in DMEM (+0.2 % BSA) without serum for an additional 24 hours. Cell growth was reinitiated by the addition of 10 % FBS with or without an experimental COX-2 inhibitor (10 μM). Twelve hours later 1 μCi ofthymidine (20 Ci/nmol) was added to each well and incubated for an additional 4 hours. The cells were washed in PBS and solubilized in 0.1 % SDS. DNA was precipitated with 10 % chilled TCA and the precipitate was collected on GFC filters. The counts in the precipitate were determined by scintillation counting. The results are shown in Fig. 4. The values represent the mean ± the standard error for triplicate determinations.
The addition of 10 μM COX-2 inhibitor did not have any effect on control cells. In contrast, the COX-2 inhibitor specifically inhibited DNA synthesis in Gα12QL-NIH3T3 cells as shown in Fig. 4. These results indicated that the COX-2-inhibitor did not affect normal cells but arrested cell growth in transformed cells dependent on the COX-2 pathway for cell growth and survival. Since Gα12QL-NIH3T3 cells exhibit such a phenotype, the bioassay system based on Gα12QL-NIH3T3 cells may be effectively used to screen putative COX-2 inhibitors.
Example 3 Determination of Prostaglandin Levels as an Assay for COX-2
Activity
Activation of prostaglandin release by NIH3T3 cells in response to Gα12QL expression was determined by monitoring prostaglandin production. Prostaglandin PGE2 was used as an index of COX-2 mediated prostaglandin production. Control NIH3T3 cells stably transfected with pcDNA3 vector and Gα12QL-transformed NIH3T3 cells were plated at 3 x 106 cells per 100 mm dish and grown overnight at 37°C in DMEM containing 5 % FBS. The cells were washed and made quiescent by placing them in DMEM (+0.2 % BSA) without serum for an additional 24 hours. Cell growth was reinitiated by the addition of 10% FBS. Six hours later the cells were pelleted by centrifugation. The cell pellet was lysed and total cellular PGE2 production was measured using a competitive enzyme immunoassay (Prostaglandin E2 EIA (enzymeimmunoassay) Kit, Cayman Chemical Co., Ann Arbor, Ml, USA) as per the manufacturer's protocol. The results are shown in Fig. 5. The values represent the mean + the standard error for triplicate determinations.
Stable expression of Gα12QL dramatically activated prostaglandin PGE2 production in the indicator cells in contrast to control NIH3T3 cells stably transfected with pcDNA3 as shown in Fig. 5. Activation or inhibition of COX-2 activity in Gα12QL transfected indicator cells can be assessed by determining the levels of prostaglandins produced by such indicator cells. The assay may be used to screen candidate compounds for inhibition of COX-2 activity.
Example 4
Determination of Arachidonic Acid Levels as an Assay for COX-2
Activity
Arachidonic acid release levels can be used as an index of COX-2 activity. Control NIH3T3 cells stably transfected with pcDNA3 vector and Gα12QL-transformed NIH3T3 cells were plated at 2 x 104 cells per well in a 24-well plate and grown for 24 hours at 37 °C in DMEM containing 5 % FBS. Cells were labeled and made quiescent by incubation for 24 hrs with 0.5 ml serum free DMEM containing 10 mM HEPES (ph 7.4), 0.2 % BSA and 0.5 μC\ [3H]-arachidonic acid per well. Cells were then washed three times with PBS to remove free [3H]-arachidonic acid. Cell growth was reinitiated by the addition of FBS to a final concentration of 5 %. [3H]- Arachidonic acid release into the surrounding media was measured at 0, 2, 5, 10, and 20 min after serum stimulation by scintillation counting as per the method of Xu et al., supra. Prior to scintillation counting cell debris in the media was removed by centrifugation at 2000 g. [3H]-arachidonic acid release by non-serum stimulated cells into the surrounding media was measured at 0, 2, 5, 10, and 20 min by scintillation counting. The results are shown in Fig. 6A. The values represent the mean ± the standard error for triplicate determinations. Serum stimulation of Gα12QL transfected cells dramatically increased arachidonic acid release in contrast to non-serum stimulated indicator cells as shown in Fig. 6A. Arachidonic acid release by control NIH3T3 cells stably transfected with pcDNA3 was unaffected by serum stimulation as shown in Fig. 6A. Activation or inhibition of COX-2 activity in Gα12QL transfected indicator cells can be assessed by determining the levels of arachidonic acid produced by such indicator cells. Inhibition of
COX-2 will presumably increase arachidonic acid levels as such inhibition will prevent conversion of arachidonic acid into the various prostaglandins.
Arachidonic acid release levels were also used as an index of COX- 2 activity in NIH3T3 cells stably transfected with pcDNA3, ras, Gα12QL, and Gα13QL expression vectors as shown in Fig. 6B. Cells were plated, labeled with [3H]-arachidonic acid, and [3H]-arachidonic acid release was measured using the methodologies described above. [3H]-arachidonic acid release was measured by scintillation counting 10 min after reinitiation of cell growth by addition of 5% FBS. The results are shown in Fig. 6B. The values represent the mean + the standard error for quadruplicate determinations.
As Fig.6B shows, serum stimulation of Gα12QL transfected indicator cells dramatically increased arachidonic acid release relative to cells stably transfected with pcDNA3, ras, or Gα13QL expression vectors as shown in Fig. 6A. These results demonstrate the apparent specificity with which Gα12QL expression stimulates the COX-2 pathway. Activation or inhibition of COX-2 activity in Gα12QL transfected indicator cells can be assessed by determining the levels of arachidonic acid produced by such indicator cells. The assay may be used to screen candidate compounds for inhibition of COX-2 activity. All references cited with respect to synthetic, preparative and analytical procedures are incorporated herein by reference. All sequence records identified by GenBank accession numbers are incorporated herein by reference. The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, ratherthan to the foregoing specification, as indication the scope of the invention.

Claims

What is claimed is:
1. A method for screening a test substance for COX-2 inhibitory activity comprising:
(a) contacting the test substance with indicator cells which constitutively express endogenous COX-2 or inducibly express endogenous COX-2; and
(b) determining the level of:
(i) proliferation of the indicator cells in the presence and absence of the test substance, a decreased level of proliferation of the indicator cells in the presence of the test substance indicating that the test substance has COX-2 inhibitory activity; or
(ii) one or more prostaglandins produced by the indicator cells in the presence and absence of the test substance, a decreased prostaglandin level in the presence of the test substance indicating that the test substance has COX-2 inhibitory activity.
(iii) arachidonic acid produced by the indicator cells in the presence and absence of the test substance, an increased arachidonic acid level in the presence of the test substance indicating that the test substance has COX-2 inhibitory activity.
2. A method for screening a test substance for COX-2 inhibitory activity comprising:
(a) contacting the test substance with indicator cells which express a GTPase-deficient mutant form of the α-subunit of protein G12, which mutant α-subunit has the capacity to induce the production of arachidonic acid and COX-2 in the indicator cells; and
(b) determining the level of proliferation of the indicator cells in the presence and absence of the test substance, a decreased level of proliferation of the indicator cells in the presence of the test substance indicating that the test substance has COX-2 inhibitory activity.
3. A method according to claim 2 wherein the G12 protein α- subunit mutant comprises the Q229L mutation.
4. A method according to claim 3 wherein the level of indicator cell proliferation is determined by an assay for DNA synthesis by the indicator cells.
5. A method according to claim 4 wherein the DNA synthesis assay comprises assaying tritium-labeled thymidine uptake by the indicator cells.
6. A method for screening a test substance for COX-2 inhibitory activity comprising:
(a) contacting the test substance with indicator cells which express a GTPase-deficient mutant form of the α-subunit of protein G12, which mutant α-subunit has the capacity to induce the production of arachidonic acid and COX-2 in the indicator cells; and
(b) determining the level of one or more prostaglandins produced by the indicator cells in the presence and absence of the test substance, a decrease in production of said prostaglandin by the indicator cells in the presence of the test substance indicating that the test substance has COX- 2 inhibitory activity.
7. A method according to claim 6 wherein the G12 protein α- subunit mutant comprises the Q229L mutation.
8. A method according to claim 7 wherein the prostaglandin level is assayed in the media surrounding the indicator cells, in the indicator cells or in a component of the indicator cells.
9. A method according to claim 8 wherein the prostaglandin level is assayed by a prostaglandin immunoassay.
10. A method according to claim 9 wherein the prostaglandin immunoassay comprises a competitive immunoassay.
12. A method for screening a test substance for COX-2 inhibitory activity comprising:
(a) contacting the test substance with indicator cells which express a GTPase-deficient mutant form of the α-subunit of protein G12, which mutant α-subunit has the capacity to induce the production of arachidonic acid and COX-2 in the indicator cells; and
(b) determining the level of arachidonic acid provided by the indicator cells in the presence and absence of the test substance, an increase in the level of arachidonic acid provided by the indicator cells in the presence of the test substance indicating that the test substance has COX-2 inhibitory activity.
13. A method according to claim 12 wherein the G12 protein α- subunit mutant comprises the Q229L mutation.
14. A method according to claim 13 wherein the arachidonic acid level is assayed in the media surrounding the indicator cells, in the indicator cells or in a component of the indicator cells.
15. A method according to claim 14 wherein the arachidonic acid assay comprises assaying tritium labeled arachidonic acid release from said indicator cells.
CELL-BASED ASSAY FOR SCREENING COX-2 INHIBITORS
PCT/US2000/016486 1999-06-16 2000-06-15 Cell-based assay for screening cox-2 inhibitors Ceased WO2000077245A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/018,581 US6933128B1 (en) 1999-06-16 2000-06-15 Cell-based assay for screening cox-2 inhibitors
EP00941446A EP1187934A4 (en) 1999-06-16 2000-06-15 CELL-BASED ASSAY FOR SCREENING COX-2 INHIBITORS
CA002374676A CA2374676A1 (en) 1999-06-16 2000-06-15 Cell-based assay for screening cox-2 inhibitors
AU56152/00A AU5615200A (en) 1999-06-16 2000-06-15 Cell-based assay for screening cox-2 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13956999P 1999-06-16 1999-06-16
US60/139,569 1999-06-16

Publications (2)

Publication Number Publication Date
WO2000077245A1 true WO2000077245A1 (en) 2000-12-21
WO2000077245A9 WO2000077245A9 (en) 2002-06-20

Family

ID=22487303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/016486 Ceased WO2000077245A1 (en) 1999-06-16 2000-06-15 Cell-based assay for screening cox-2 inhibitors

Country Status (4)

Country Link
EP (1) EP1187934A4 (en)
AU (1) AU5615200A (en)
CA (1) CA2374676A1 (en)
WO (1) WO2000077245A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267218A (en) * 2017-05-26 2019-07-31

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
AT402732B (en) * 1996-02-16 1997-08-25 Nycomed Austria Gmbh Use of the human megakaryocytic cell line dami for identifying and determining substances for inhibiting the enzymatic activity of the enzyme cyclooxygenase-1
AT402936B (en) * 1996-05-29 1997-09-25 Nycomed Austria Gmbh Use of a human cell line for identifying and determining substances for inhibiting the induction of the expression of the cyclooxygenase-2 gene

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRIDEAU ET AL.: "A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors", INFLAMM. RES., vol. 45, 1 February 1996 (1996-02-01), pages 68 - 74, XP002933439 *
LAUFER ET AL.: "Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors", INFLAMM. RES., vol. 48, 1 March 1999 (1999-03-01), pages 133 - 138, XP002933438 *
MCCORMACK K.: "Roles of COX-1 and COX-2", J. RHEUMATOL., vol. 25, 1 November 1998 (1998-11-01), pages 2279 - 2281, XP002933440 *
See also references of EP1187934A4 *
XU N. ET AL.: "A mutant alpha subunit of G12 potentiates the eicosanoid pathway and is highly oncogenic in NIH 3T3", PROC. NATL. ACAD. SCI. USA, vol. 90, 1 July 1993 (1993-07-01), pages 6741 - 6745, XP002933441 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267218A (en) * 2017-05-26 2019-07-31
CN110167547A (en) * 2017-05-26 2019-08-23 欧亚制药有限责任公司 For treating new more target agents of disease in mammals
EP3632424A4 (en) * 2017-05-26 2021-03-03 "Pharmenterprises Eurasia" Limited Liability Company NEW PREPARATIONS TO TREAT DISEASES IN MAMMALS
IL267218B2 (en) * 2017-05-26 2023-05-01 Pharmenterprises Eurasia Llc Novel multitarget drug for treating diseases in mammals
CN110167547B (en) * 2017-05-26 2024-04-05 欧亚制药有限责任公司 Multi-target drugs for treating diseases in mammals

Also Published As

Publication number Publication date
AU5615200A (en) 2001-01-02
WO2000077245A9 (en) 2002-06-20
EP1187934A1 (en) 2002-03-20
CA2374676A1 (en) 2000-12-21
EP1187934A4 (en) 2002-07-31

Similar Documents

Publication Publication Date Title
Kobayashi et al. The c‐Cbl/CD2AP complex regulates VEGF‐induced endocytosis and degradation of Flt‐1 (VEGFR‐1)
KR100529270B1 (en) Promotion or Inhibition of Angiogenesis and Cardiovascularization
JP2002516064A (en) Human signaling serine / threonine kinase
Polek et al. The TNF receptor, RELT, binds SPAK and uses it to mediate p38 and JNK activation
KR20040088077A (en) Promotion or Inhibition of Angiogenesis and Cardiovascularization
US6933128B1 (en) Cell-based assay for screening cox-2 inhibitors
TW200538109A (en) Furosemide modulators of HM74
WO2000077245A1 (en) Cell-based assay for screening cox-2 inhibitors
US6872558B1 (en) Heparanase-2 a member of the heparanase protein family
WO2005019472A1 (en) Method of detecting effect of controlling synoviolin activity
WO2000009678A1 (en) Irak3 polypeptides, polynucleotides and methods
JP3842130B2 (en) Phosphatase that activates the MAP kinase pathway
JP2004089190A (en) Human myt-1 kinase clone
KR20050052663A (en) Inducible focal adhesion kinase cell assay
WO2001038371A1 (en) A NOVEL POLYPEPTIDE-HUMAN GLUTAMATE tRNA SYNTHETASE 58 AND THE POLYNUCLEOTIDE ENCODING SAID POLYPEPTIDE
JP4746537B2 (en) Gene encoding guanine nucleotide exchange factor and gene product thereof
EP1227150B1 (en) Androgen receptor complex-associated protein
JP4674332B2 (en) Txk complex and use thereof
US7078478B2 (en) Inhibition of the proliferation of cells of the multiple myeloma
JP2003532424A (en) RH116 polypeptides and fragments thereof, and polynucleotides encoding said polypeptides and therapeutic uses
WO2005103257A1 (en) GENE ENCODING GUANINE NUCLEOTIDE EXCHANGE FACTOR BINDING TO RhoA
KR20070033428A (en) Methods and assays for detecting guanylate cyclase activity
US20030186254A1 (en) Regulation of HIV-Tat and Nef by PAK4 kinase and its binding partners and methods of identifying modulators thereof
JPWO2007058336A1 (en) Screening method and identification method of degranulation reaction inhibitory substance or prostaglandin D2 production inhibitory substance of mast cell via Rec168, and therapeutic agent for inflammatory disease comprising the substance
JP2004500864A (en) Novel G-protein coupled receptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2374676

Country of ref document: CA

Ref country code: CA

Ref document number: 2374676

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000941446

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10018581

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000941446

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 25, CLAIMS, REPLACED BY A NEW PAGE 25; PAGE 1/7, DRAWINGS, REPLACED BY A NEW PAGE 1/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000941446

Country of ref document: EP